Monoclonal antibody inhibitor of GM-CSF, IL-3, IL-5 and other cytokines, and uses thereof
OwnerAngel Lopez, Richard D'Andreainventors
Life of this patent
Estimating the term…
Loading patent…
OwnerAngel Lopez, Richard D'Andreainventors
Estimating the term…
A method of isolating a monoclonal antibody capable of inhibiting any one of IL-3, GM-CSF and IL-5 binding to the common receptor βc or a monoclonal antibody capable of inhibiting the cytokines binding to a receptor analogous to βc. The method includes the steps of immunizing an animal with a cytokine receptor or portion of a cytokine containing the critical binding site which portion includes the extracellular domain 4 or an analogous domain in the analogous common receptor or part thereof. Antibodies producing cells from the animal are then isolated and fused with a myeloma cell line and then screened for a cell line that produces an antibody of the desired type. A monoclonal antibody, or fragments thereof capable of inhibiting the binding of the cytokines IL-3, GM-CSF and IL-5 to the βc receptor, and a hybridoma cell line producing the antibody are also claimed.
A monoclonal antibody or fragments thereof capable of inhibiting the binding of cytokines IL-3, GM-CSF and IL-5 to the common receptor βc, subunit wherein the monoclonal antibody or fragments thereof binds to both the B′-C′ loop and the F′-G′ of domain 4 of the βc subunit.
A monoclonal antibody produced by the hybridoma cell line deposited as accession number ATCC HB-12525.
The hybridoma cell line ATCC HB-12525.
A method of identifying an inhibitor capable of competitively inhibiting the binding of BION-1 to the βc subunit, the method including the steps of contacting BION-1 or fragment thereof with the βc subunit as well as a candidate inhibitory compound,
Dependencies are inferred from the claim text.